%0 Journal Article
%A Fernández Arrabal, José Antonio
%A Salazar Corral, Juan José
%A Hoz Montañana, María Rosa De
%A Marco López, Eva María
%A Martín Sánchez, Beatriz
%A Flores Salguero, Elena
%A García Martín, Elena Salobrar
%A López Cuenca, Inés
%A Barrios Sabador, Vicente
%A Avilés Trigueros, Marcelino
%A Valiente Soriano, Francisco Javier
%A Miralles de Imperial-Ollero, Juan A.
%A Vidal Sanz, Manuel
%A Triviño Casado, Alberto
%A Ramírez Sebastián, José Manuel
%A López Gallardo, Meritxell
%A Ramírez Sebastián, Ana Isabel
%T Retinal Molecular Changes Are Associated with Neuroinflammation and Loss of RGCs in an Experimental Model of Glaucoma
%D 2021
%@ 1422-0067
%U https://hdl.handle.net/20.500.14352/7890
%X Signaling mediated by cytokines and chemokines is involved in glaucoma-associated neuroinflammation and in the damage of retinal ganglion cells (RGCs). Using multiplexed immunoassay and immunohistochemical techniques in a glaucoma mouse model at different time points after ocular hypertension (OHT), we analyzed (i) the expression of pro-inflammatory cytokines, anti-inflammatory cytokines, BDNF, VEGF, and fractalkine; and (ii) the number of Brn3a+ RGCs. In OHT eyes, there was an upregulation of (i) IFN-γ at days 3, 5, and 15; (ii) IL-4 at days 1, 3, 5, and 7 and IL-10 at days 3 and 5 (coinciding with downregulation of IL1-β at days 1, 5, and 7); (iii) IL-6 at days 1, 3, and 5; (iv) fractalkine and VEGF at day 1; and (v) BDNF at days 1, 3, 7, and 15. In contralateral eyes, there were (i) an upregulation of IL-1β at days 1 and 3 and a downregulation at day 7, coinciding with the downregulation of IL4 at days 3 and 5 and the upregulation at day 7; (ii) an upregulation of IL-6 at days 1, 5, and 7 and a downregulation at 15 days; (iii) an upregulation of IL-10 at days 3 and 7; and (iv) an upregulation of IL-17 at day 15. In OHT eyes, there was a reduction in the Brn3a+ RGCs number at days 3, 5, 7, and 15. OHT changes cytokine levels in both OHT and contralateral eyes at different time points after OHT induction, confirming the immune system involvement in glaucomatous neurodegeneration.
%~